Shaomeng Wang, PhD
Warner-Lambert/Parke-Davis Professor of Medicine
Professor of Internal Medicine
Professor of Pharmacology
Professor of Medicinal Chemistry
College of Pharmacy
[email protected]

Available to mentor
Shaomeng Wang, PhD
Professor
  • Center Memberships
  • Recent Publications
    • Center Memberships
    • Center Member
      Center for Computational Medicine and Bioinformatics
    • Center Member
      Rogel Cancer Center
    Recent Publications See All Publications
    • Journal Article
      Proteomic screens of SEL1L-HRD1 ER-associated degradation substrates reveal its role in glycosylphosphatidylinositol-anchored protein biogenesis.
      Wei X, Lu Y, Lin LL, Zhang C, Chen X, Wang S, Wu SA, Li ZJ, Quan Y, Sun S, Qi L. Nat Commun, 2024 Jan 22; 15 (1): 659 DOI:10.1038/s41467-024-44948-2
      PMID: 38253565
    • Journal Article
      Corrigendum to "Characterizing the Therapeutic Potential of a Potent BET Degrader in Merkel Cell Carcinoma" [Neoplasia, Volume 21, Issue 3 (2019) 322-330].
      Choi JE, Verhaegen ME, Yazdani S, Malik R, Harms PW, Mangelberger D, Tien J, Cao X, Wang Y, Cieślik M, Gurkan J, Yazdani M, Jing X, Juckette K, Su F, Wang R, Zhou B, Apel IJ, Wang S, Dlugosz AA, Chinnaiyan AM. Neoplasia, 2024 Sep; 55: 101019 DOI:10.1016/j.neo.2024.101019
      PMID: 38943995
    • Journal Article
      3D reconstruction of the mouse cochlea from scRNA-seq data suggests morphogen-based principles in apex-to-base specification.
      Wang S, Chakraborty S, Fu Y, Lee MP, Liu J, Waldhaus J. Dev Cell, 2024 Jun 17; 59 (12): 1538 - 1552.e6. DOI:10.1016/j.devcel.2024.03.028
      PMID: 38593801
    • Journal Article
      Off-target autophagy inhibition by SHP2 allosteric inhibitors contributes to their anti-tumor activity in RAS-driven cancers.
      Miao Y, Bai Y, Miao J, Murray AA, Lin J, Dong J, Qu Z, Zhang R-Y, Nguyen QD, Wang S, Yu J, Nguele Meke F, Zhang Z-Y. J Clin Invest, 2024 Jun 6; DOI:10.1172/JCI177142
      PMID: 38842946
    • Preprint
      p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer.
      Luo J, Chen Z, Qiao Y, Tien JC-Y, Young E, Mannan R, Mahapatra S, He T, Eyunni S, Zhang Y, Zheng Y, Su F, Cao X, Wang R, Cheng Y, Seri R, George J, Shahine M, Miner SJ, Vaishampayan U, Wang M, Wang S, Parolia A, Chinnaiyan AM. 2024 May 23; DOI:10.1101/2024.03.29.587346
      PMID: 38586029
    • Journal Article
      Corrigendum to 'Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment' Neoplasia, Volume 22, Issue 2 (2020) 111-119.
      Kregel S, Wang C, Han X, Xiao L, Fernandez-Salas E, Bawa P, McCollum BL, Wilder-Romans K, Apel IJ, Cao X, Speers C, Wang S, Chinnaiyan AM. Neoplasia, 2024 May; 51: 100986 DOI:10.1016/j.neo.2024.100986
      PMID: 38492449
    • Journal Article
      Corrigendum to "Characterizing the Therapeutic Potential of a Potent BET Degrader in Merkel Cell Carcinoma" [Neoplasia, Volume 21, Issue 3 (2019) 322-330].
      Choi JE, Verhaegen ME, Yazdani S, Malik R, Harms PW, Mangelberger D, Tien J, Cao X, Wang Y, Cieślik M, Gurkan J, Yazdani M, Jing X, Juckette K, Su F, Wang R, Zhou B, Apel IJ, Wang S, Dlugosz AA, Chinnaiyan AM. Neoplasia, 2024 May; 51: 100995 DOI:10.1016/j.neo.2024.100995
      PMID: 38574506
    • Journal Article
      Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression.
      Chen Z, Wang M, Wu D, Bai L, Xu T, Metwally H, Wang Y, McEachern D, Zhao L, Li R, Takyi-Williams J, Wang M, Wang L, Li Q, Wen B, Sun D, Wang S. J Med Chem, 2024 Apr 11; 67 (7): 5275 - 5304. DOI:10.1021/acs.jmedchem.3c02124
      PMID: 38477974